Latest News and Press Releases

Ad hoc announcement pursuant to Art. 53 LR The proposed amendments to the terms of the 2025 convertible bond have been approved by the bondholders and will become binding and effective upon approval...

Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the terms of the resolutions to be voted uponUnaudited...

Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland – January 15,...

Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on February 25, 2025, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on January...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025Idorsia Ltd (SIX: IDIA) today announced that – in the coming days – the company intends to publish an invitation to...

Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company’s...

Ad hoc announcement pursuant to Art. 53 LR Company enters into exclusive negotiations with an undisclosed party for global rights to aprocitentanCompany to streamline the business, resulting in cost...

Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net...

Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of...